Nearly a decade after spinning its Shanghai research operation into what became Dizal Pharmaceutical, AstraZeneca has agreed to pay USD 600 million upfront to reacquire worldwide rights to the company's lead oncology asset, Zegfrovy (sunvozertinib), highlighting both the maturation of China's innovative biotech sector and the long-term value created by its former China R&D organization.
Under the agreement, AstraZeneca will obtain exclusive global development and commercialization rights to the oral EGFR inhibitor for non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations. Dizal is eligible to receive up to an additional USD 900 million in development, regulatory and commercial milestones, plus tiered royalties on worldwide net sales. The transaction is expected to close in H2 2026.
The deal is notable not only for its economics but also for its history. Dizal was established in 2017 after AstraZeneca and China's State Development & Investment Corp. (SDIC) created a joint venture around AstraZeneca's Shanghai Innovation Center, transferring the company's local discovery capabilities into an independent drug developer. Sunvozertinib has since become one of the most successful oncology assets to emerge from that organization, and AstraZeneca is now bringing the program back into its global portfolio following US approval.
Unlike most China-out licensing transactions, the agreement transfers worldwide rights, including China, where Zegfrovy is already approved and commercially marketed. Chinese biopharma companies have typically retained domestic commercialization rights while licensing overseas markets to multinational partners. By acquiring global rights, AstraZeneca gains full strategic control over the product across all major markets.
The premium economics also reflect the asset's unusually advanced regulatory position. The US FDA granted accelerated approval for Zegfrovy on July 2, 2026, with the licensing agreement announced less than two weeks later. Unlike many China-origin licensing transactions centered on earlier-stage assets, AstraZeneca is acquiring a commercially approved product with regulatory uncertainty in its initial indication largely removed.
Sunvozertinib is a once-daily irreversible EGFR inhibitor designed to selectively target exon 20 insertion mutations while sparing wild-type EGFR, an approach intended to reduce the dermatologic and gastrointestinal toxicities associated with less selective EGFR inhibitors. The mutation subtype has historically been difficult to treat because of its limited sensitivity to earlier generations of EGFR-targeted therapies.
The drug has already established a substantial clinical foundation. US approval was supported by the multinational WU-KONG1 Part B study, while approval in China was based on WU-KONG6. More recently, the multinational Phase III WU-KONG28 trial met its primary endpoint in treatment-naive patients, demonstrating a statistically significant improvement in progression-free survival over platinum-doublet chemotherapy (10.3 months versus 7.5 months; hazard ratio 0.65; p=0.0008), with an objective response rate of 68.1% compared with 35.4%. The results were presented as a late-breaking oral presentation at ASCO 2026 and published simultaneously in The New England Journal of Medicine. Supplemental applications have been submitted in both the US and China for first-line treatment, where the therapy has also received Breakthrough Therapy Designation from both regulators.